March 27, 2008 8:00AM Eastern Daylight Time

Azopharma Announces Further Expansion of CTM Manufacturing Capabilities HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to significantly expand its manufacturing capabilities at its Hollywood and Miramar, Florida sites with the addition of 17 new manufacturing suites. The new suites would bring the company’s total to 29 and further solidify Azopharma’s position as a leader in the development and manufacturing of clinical trial material (CTM).

The new suites focus on expanding Azopharma’s ability to make material under GMP and sterile conditions as well as work with cytotoxic and potent compounds. As a leading industry expert in pharmaceutical and medical device product development, Azopharma offers the full spectrum of development services from preclinical assessments to commercialization. According to Phil Meeks, Azopharma Chief Executive Officer, “This expansion will help us to meet the growing needs of the cytotoxic market which has seen steady growth for the past few years” Mr. Meeks continues, “This expansion will also help us more fully serve our clients’ needs for total product development. There are few companies in the industry which can provide the scope of services that we do and fewer still that can work with cytotoxic and potent compounds” New manufacturing suites include: 

  · Eleven GMP Suites
  · Two Cytotoxic Suites
  · One Sterile Suite
  · One Sterile Cytotoxic Suite 
  · Two Explosion Proof Suites 

Azopharma’s expansion ensures our clients’ projects are completed with the very best in state-of-the-art equipment and facilities continuing our legacy of quality service in total product development.

Azopharma Product Development Group brings together the best scientists in the field, state-of-the-art facilities and a focus on quality that provides our client partners an unbeatable combination in total product development. Azopharma Product Development Group Includes:
 
     · Azopharma Contract Pharmaceutical Services - Integrated product development and CTM manufacturing for 
                                                                                                  all  dosage forms. 

    · ApiCross Drug Delivery Technologies - Proprietary drug delivery platforms to solve difficult molecular
                                                                               challenges. 

    · Cyanta Analytical Laboratories - Analytical chemistry and inhalation services from development to quality 
                                                                  control testing.

   · AniClin Preclinical Services - Preclinical services in support of early product development. 

   · IQsynthesis - Synthetic chemistry services from discovery to clinical API supplies including large scale API
                             synthesis. 

  · AvivoClin Clinical Services - Human clinical pharmacology services for Phase I/II/III clinical trials.

  · ADMEquant Bioanalytical Services - Bioanalytical research analysis of pharmaceutical compounds in all 
                                                                        matrices. 

About Azopharma Azopharma Product Development Group is FDA registered, DEA approved and client audited on a regular basis. Azopharma’s mission is to help our customers turn Ideas Into Cures™. In product development, it comes down to the right people, their commitment and application of experience.

Partnering with Azopharma provides customers with the confidence of assured success. We welcome visits to our South Florida facilities as well as our other sites to conduct audits or meet with our pharmaceutical scientists to outline a study that meets your specific needs.

Contact us at development@azopharma.com or 954-433-7480.
Contact Phil Meeks, CEO Azopharma Product Development Group 2 Oakwood Boulevard,
Suite 170 Hollywood, FL 33020 Phone: 954-433-7480 www.azopdogroup.com